Monthly Archives:September 2017
Time to switch? Switching from innovator rituximab to biosimilar CT-P10 is safe and efficacious
Rituximab is a monoclonal antibody that targets the CD20 protein that is found mainly on immune cells called B lymphocytes. By removing CD20-positive B lymphocytes from the peripheral blood and bone marrow, rituximab provides effective treatment for
Non-canonical Wnt signaling and aortic valve stenosis
p38α MAP kinase inhibition in atherosclerosis – a new therapeutic tool?
Why is the transcription factor Pax8 necessary for a functional thyroid gland?
Hot or Not – The Heat Shock Factor1 (HSF1) is essential for Candida albicans cellular functioning
Long-term safety and efficacy of rituximab biosimilar CT-P10 in rheumatoid arthritis
Rituximab is a monoclonal antibody used to treat certain cancers of the blood, as well as immune-mediated diseases such as rheumatoid arthritis. But while rituximab is effective, it is also expensive, which means that not everyone who
The Oriental Region: the last frontier paradise for black flies
9th World Biomarkers Congress. Madrid, Spain. December 07-08, 2017
On the spider that spits the solution of a nonsmooth oscillator
10th Annual European Pharma Congress. Frankfurt, Germany. May 07-09, 2018
Down to the last Drop: A single red blood cells is all that is needed to identify blood at a crime scene
Migration led to the microevolution of Chinese short fat-tailed Sheep
Revisiting the RNA World with its inventor
The RNA World Hypothesis is a model for the early evolution of life on earth proposed in 1986 by the molecular biologist Walter Gilbert, in which he posited that the earliest forms of life were likely composed